More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$58.81B
EPS
19.57
P/E ratio
42.1
Price to sales
12.33
Dividend yield
--
Beta
0.486783
Previous close
$950.95
Today's open
$935.68
Day's range
$934.66 - $952.37
52 week range
$661.85 - $1,072.75
show more
CEO
Tim Van Hauwermeiren
Employees
1863
Headquarters
Amsterdam,
Exchange
Nasdaq Global Select
Shares outstanding
62062888
Issue type
American Depository Receipt
Healthcare
Biotechnology & Life Sciences
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire • Nov 12, 2026

3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade
Argenx's Vyvgart franchise addresses about 28,000 patients today, with the company targeting 60,000 by 2030. The biotech is solidly profitable, with Q3 revenue up 54% and $3.7 billion in cash to fund growth.
The Motley Fool • Nov 9, 2026

argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
Amsterdam, the Netherlands, November 9, 2026, 07:00 CET – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced a definitive agreement to acquire Unnatural Products, Inc. (UNP), adding a macrocyclic peptide discovery engine to its immunology innovation capabilities. argenx, which already holds a minority stake in UNP, will acquire all remaining shares in a transaction valuing UNP at up to approximately $1.15 billion across upfront and milestone payments. This acquisition expands the ways argenx can pursue novel biology and develop oral or long-acting medicines for people living with serious immune-mediated diseases.
GlobeNewsWire • Nov 9, 2026

Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
Argenx to acquire UNP for $550 million upfront plus contingent value rights tied to development and regulatory milestones, for total potential value of up to approximately $1.15 billion
GlobeNewsWire • Nov 9, 2026

argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis
ALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM population First Phase 3 study to demonstrate statistically significant and clinically meaningful benefit in IMNM, an autoimmune myositis subtype with no approved therapies Consistent, clinically meaningful treatment effect in DM, demonstrating improvements in muscle strength and skin disease activity November 7, 2026, 10:00 AM ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced that data from the Phase 3 ALKIVIA study demonstrating rapid and sustained improvement with VYVGART ® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in patients with autoimmune myositis will be featured in a late-breaking oral presentation (#LB24) at the American College of Rheumatology (ACR) Convergence 2026 on November 11, 2026, from 9:15-9:30 a.m. ET. Combined IMNM and DM population: Primary and key secondary endpoints met The study met its primary endpoint in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) patient population, demonstrating that patients treated with efgartigimod achieved a statistically significant and clinically meaningful 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 versus placebo (p=0.0011; 48.0 vs 32.6).
GlobeNewsWire • Nov 7, 2026

Best Biotech Stocks to Buy Now as AI Stocks Tank: ARGX
Investors should consider buying resurgent healthcare and biotech stocks amid the AI selloff. Today, we are digging into why it might be time to buy biopharmaceutical stock Argenx (ARGX).
Zacks Investment Research • Nov 4, 2026

argenx to Present at Upcoming Investor Conferences
November 3, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced that members of the management team will participate in the following investor conferences in November: Guggenheim 3rd Annual Healthcare Innovation Conference. Fireside chat on Tuesday, November 10 at 2:00 p.m.
GlobeNewsWire • Nov 3, 2026

argenx: 3 Key Takeaways for Long-Term Investors
Product net sales reached $1.7 billion, growing 54% year over year. Operating profit reached $486 million with a 28% operating margin.
The Motley Fool • Oct 23, 2026

Argenx Slumps On Mixed Third Quarter, Surprise Vyvgart Testing Plans
Argenx stock fell early Thursday despite beating sales expectations on a surprise testing requirement for its drug, Vyvgart.
Investors Business Daily • Oct 22, 2026

What argenex (ARGX) Said on Its Q3 Earnings Call
argenex NASDAQ: ARGX reported third-quarter 2026 product net sales of $1.7 billion, up 54% from a year earlier and 13% sequentially, as patient growth in generalized myasthenia gravis, or MG, and chronic inflammatory demyelinating polyneuropathy, or CIDP, continued to support demand for VYVGART.
MarketBeat • Oct 22, 2026

¹ Disclosures

Open an M1 investment account to buy and sell argenx SE commission-free¹. Build wealth for the long term using automated trading and transfers.